// App-Quantinova.ai

CT214 : Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

Researchers

Presenter

  • Bruce E. Johnson

Principal Investigators

  • Tae Min Kim

  • T. Jeroen N. Hiltermann

  • Fabrice Barlesi

  • Christian Grohe

  • Yasushi Goto

  • Orvar Gunnarsson

  • Tobias Overbeck

  • Noemi Reguart

  • Martin Wermke

  • Gilberto Castro Castro

  • Enriqueta Felip

  • Alastair Greystoke

  • Benjamin J. Solomon

  • Stephanie Deudon

  • Anne-Laure Louveau

  • Vanessa Passos

  • Daniel SW Tan

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Universitair Medisch Centrum Groningen, Groningen, Netherlands

  • Aix Marseille University, Marseille, France

  • Evangelische Lungenklinik Berlin, Berlin, Germany

  • National Cancer Center Hospital, Tokyo, Japan

  • Landspitali Unversity Hospital, Reykjavik, Iceland

  • University Hospital Göttingen - University Medical Centre Göttingen, Groningen, Germany

  • Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

  • Uniklinikum Dresden, Dresden, Germany

  • Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Newcastle upon Tyne Hospitals, High Heaton, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Novartis AG, Basel, Switzerland

  • Novartis Pharma S.A.S., Rueil-Malmaison, France

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • National Cancer Centre Singapore, Singapore, Singapore

Locations

  • United States

  • Republic of South Korea

  • Netherlands

  • France

  • Germany

  • Japan

  • Iceland

  • Spain

  • Brazil

  • United Kingdom

  • Australia

  • Switzerland

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral neuropathy

  • Cardiac tamponade

  • Coronary Artery Disease

  • Constipation

  • Lung Cancer

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Cancer antigen 15-3

  • Programmed cell death protein 1

  • Cytokine

  • Interleukin 1 beta

Drug/Treatment

  • Pembrolizumab

  • canakinumab (SC)

  • Carboplatin

  • Interleukin

  • Paclitaxel

  • Pemetrexed

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

  • Cohort

Phase

  • NA

Study Id's

  • NCT03631199

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved